Quantum Biopharma Ltd (QNTM) News & EventsQNTMQuantum Biopharma Ltd

Quantum BioPharma Enters Study Start-Up Agreement with Thermo Fisher

Quantum BioPharma (QNTM) has entered into a Study Start-Up Agreement, or SUA, with the clinical research business of Thermo Fisher (TMO) to implement Quantum's Phase 2 clinical trial of Lucid-21-302 for multiple sclerosis, or MS. Following the company's receipt of FDA clearance to proceed with the planned Phase 2 clinical trial, Quantum BioPharma is advancing into implementation. Under the terms of the contract, Thermo Fisher will support Quantum BioPharma in implementing the Phase 2 clinical trial, including study start-up activities and related clinical research services. The Phase 2 trial will evaluate the efficacy, safety, and tolerability of Lucid-MS in people with progressive forms of MS. The study is designed to evaluate clinical and radiological endpoints relevant to disease progression and disease biology.

Quantum BioPharma Appoints Michael Zapolin as CEO of Unbuzzd Wellness

Quantum BioPharma announced its licensee - Unbuzzd Wellness - announces the appointment of Michael Zapolin as CEO. This marks a milestone in the Company.

Quantum BioPharma Receives FDA Approval for Lucid-MS to Enter Phase 2 Trials

Quantum BioPharma announced that the FDA has approved the company's investigational new drug, or IND, application for Lucid-MS, enabling Quantum BioPharma to immediately advance its patented multiple sclerosis program into Phase 2 clinical development. This will be the first time in history patients with MS consume the unique Lucid-MS new chemical entity molecule with a goal of reversing some or all of their loss of bodily control or mobility. Trial start-up activities, including site selection, are already underway, and the company expects to initiate patient enrollment and drug administration as quickly as possible.